Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 26, 2009
Wed, February 25, 2009 CombinatoRx to Webcast Conference Call Discussing Year End 2008 Financial Results
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it will report financial results for the year end 2008 before market opens on Wednesday, March 4, 2009 followed by a conference call at 8:30 a.m. ET in which senior management will provide an update on the company and discuss year end results.
To access the call, please dial 866-383-8003 or 617-597-5330 (international) five minutes prior to the start time and provide the passcode 15168229. A replay of the call will be available from 10:30 a.m. ET on March 4, 2009 until March 18, 2009. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the passcode 30354375.
A live audio webcast of the call will also be available on the "Investors" section of the company's website, [ www.combinatorx.com ]. An archived audio webcast will be available on the CombinatoRx website two hours after the event and will be archived for 14 days.
About CombinatoRx
CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action, striking at the biological complexities of human disease. The CombinatoRx proprietary drug discovery technology provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx, please visit [ www.combinatorx.com ].
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its product candidates, their clinical potential and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain collaboration partners or additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. These forward looking statements reflect management's current views and CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
(c) 2009 CombinatoRx, Incorporated. All rights reserved.
